Clinigen adds U.S. rights to Proleukin

Clinigen Group plc (LSE:CLIN) jumped 134.5p (18%) to 872p on Feb. 13 after the U.K. specialty pharma said it will acquire U.S. rights

Read the full 237 word article

User Sign In